Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH)
2024-512913-42-00Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in alcohol-associated hepatitis (AH) comparing INT-787 with Placebo (2 arms). Primary endpoint: Lille score response at Day 7. Started May 2024; status: completed.
02
Drugs
INT-787
03
Conditions
alcohol-associated hepatitis (AH)
Beyond the preview
Go deeper on 2024-512913-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512913-42-00.